Atlantanews Online

Delveinsight Business Research LLP

The report covers emerging Chronic Kidney Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Kidney Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Kidney Disease: An Overview

According to NIDDK, Chronic Kidney Disease (CKD) means the kidneys are damaged and can’t filter blood the way they should. Abnormalities of kidney structure or function, present for > 3 months, with implications for health are considered to be Chronic Kidney Disease. Chronic Kidney Disease is classified into five stages according to the damage to kidneys and their working. In Stage 1, there is mild kidney disease and in Stage 5 Chronic Kidney Disease, the kidneys have stopped working (kidney failure). Chronic Kidney Disease has varying levels of seriousness.

There’s no cure for Chronic Kidney Disease, but treatment can help relieve the symptoms and stop it from getting worse. The treatment plan includes lifestyle and dietary changes, and medicines to lower blood pressure, blood sugar, or cholesterol are used. Diuretics are used to help the kidneys get rid of water and lower swelling. Dialysis may be needed in some cases. A kidney transplant may be an option when the kidneys have failed as in advanced Chronic Kidney Disease.

Chronic Kidney Disease Market Key Facts

• The total market size of Chronic Kidney Disease in the 7MM was approximately USD 4,934 million in 2022 and is projected to increase during the forecast period (2023-2032)

• Among EU4 and the UK, the UK accounts for the maximum market size in 2022 while Italy occupies the bottom of the ladder in 2022.

• The US accounted for approximately 5.6 million diagnosed cases, whereas in the EU4 and the UK, there were around 6.9 million diagnosed Chronic Kidney Disease cases in 2022. 

• Japan accounted for 3.5 million diagnosed cases of Chronic Kidney Disease in 2022. These cases are expected to increase in the US, EU4, and the UK, and are expected to decrease in Japan by 2032

• Among the EU4 and the UK, the UK had the highest diagnosed prevalent population of Chronic Kidney Disease (approximately 2.3 million cases), followed by Germany (approximately 1.5 million cases) in 2022. On the other hand, Italy (0.7 million cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

Chronic Kidney Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Kidney Disease pipeline therapies. It also thoroughly assesses the Chronic Kidney Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Chronic Kidney Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Kidney Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Chronic Kidney Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Kidney Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Chronic Kidney Disease Epidemiology, Segmented as –

• Prevalent Cases of Chronic Kidney Disease

• Diagnosed Prevalent Cases of Chronic Kidney Disease

• Gender-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

• Age-specific Diagnosed Prevalent cases of Chronic Kidney Disease

• Complication-specific Diagnosed Prevalent cases of Chronic Kidney Disease

• Stage-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

• Etiology-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Kidney Disease market or expected to be launched during the study period. The analysis covers the Chronic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Kidney Disease drugs based on their sale and market share.

The report also covers the Chronic Kidney Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Kidney Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Chronic Kidney Disease Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Chronic Kidney Disease Therapeutics Analysis

Several major pharma and biotech companies are actively engaged in developing therapies for Chronic Kidney Disease, collectively contributing to advancements in treatment options. Among these companies, KBP Biosciences stands out with Chronic Kidney Disease drug candidates in an advanced stage, specifically in Phase III of clinical trials. This progress highlights a significant milestone in the quest for effective treatments for Chronic Kidney Disease, reflecting the dedication and progress within the industry to address this medical condition and improve patient outcomes.

Chronic Kidney Disease Companies Actively Working in the Therapeutics Market Include

Numerous companies are actively involved in addressing Chronic Kidney Disease (CKD), contributing their efforts towards research, development, and treatment innovations in this critical medical area. Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies Inc., MISSION Therapeutics, and AceLink Therapeutics are among the key players dedicated to advancing Chronic Kidney Disease treatments. Their collective commitment drives advancements, fostering hope for improved management and care for individuals affected by Chronic Kidney Disease.

Emerging and Marketed Chronic Kidney Disease Therapies Covered in the Report Include:

• KBP-5074: KBP Biosciences

• Ziltivekimab: Novo Nordisk

• US-APR2020: Kibow Pharma

• DM199: DiaMedica Therapeutics

• AL-01211: AceLink Therapeutics

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Kidney Disease Competitive Intelligence Analysis

4. Chronic Kidney Disease Market Overview at a Glance

5. Chronic Kidney Disease Disease Background and Overview

6. Chronic Kidney Disease Patient Journey

7. Chronic Kidney Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Chronic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Kidney Disease Unmet Needs

10. Key Endpoints of Chronic Kidney Disease Treatment

11. Chronic Kidney Disease Marketed Therapies

12. Chronic Kidney Disease Emerging Drugs and Latest Therapeutic Advances

13. Chronic Kidney Disease Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Kidney Disease Market Outlook (In US, EU5, and Japan)

16. Chronic Kidney Disease Companies Active in the Market

17. Chronic Kidney Disease Access and Reimbursement Overview

18. KOL Views on the Chronic Kidney Disease Market

19. Chronic Kidney Disease Market Drivers

20. Chronic Kidney Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Angelman Syndrome Market

“Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Angelman Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Angelman Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research